Lumira Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)Warren Douglas Sheffield(Executive Officer, Director, Promoter)
Board seatGerry Brunk· per SEC Form D
Co-investorsJAZZ Venture PartnersAngelini VenturesF-Prime CapitalIaso Ventures
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)Gail Maderis(Director)Kristine Ball(Executive Officer, Director)Elaine Chien(Executive Officer)Sarah Walter(Executive Officer)Raju Gadiraju(Executive Officer)
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersMPM BioImpactOUP (Osage University Partners)Sofinnova Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.